{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T05:29:39Z","timestamp":1670477379485},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration\u00b4s Sentinel System.<jats:bold>METHODS:<\/jats:bold> Using administrative claims data, we identified patients who filled standard LTBI treatment prescriptions\n during 2008\u20132019. In these cohorts, we assessed LTBI testing, clinical management, and treatment duration.<jats:bold>RESULTS:<\/jats:bold> Among 113,338 patients who filled LTBI prescriptions, 80% (90,377) received isoniazid (INH) only, 19% (21,235) rifampin (RIF) only, and 2% (1,726) INH + rifapentine\n (RPT). By regimen, the proportion of patients with documented prior testing for TBI was 79%, 54%, and 91%, respectively. Median therapy duration was 84 days (IQR 35\u201384) for the 3-month once-weekly INH + RPT regimen, 60 days (IQR 30\u2013100) for the 6- to 9-month INH regimen, and 30\n days (IQR 2\u201360) for the 4-month RIF regimen.<jats:bold>CONCLUSIONS:<\/jats:bold> Among the cohorts, INH-only was the most commonly prescribed LTBI treatment. Most persons who filled a prescription for LTBI treatment did not have evidence of completing recommended treatment duration. These data further\n support preferential use of shorter-course regimens such as INH + RPT.<\/jats:p>","DOI":"10.5588\/ijtld.22.0259","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T04:43:05Z","timestamp":1669783385000},"page":"1170-1176","source":"Crossref","is-referenced-by-count":0,"title":["Using the Food and Drug Administration\u00b4s Sentinel System for surveillance of TB infection"],"prefix":"10.5588","volume":"26","author":[{"given":"W. L.","family":"Walker","sequence":"first","affiliation":[{"name":"Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. M.","family":"Schmit","sequence":"additional","affiliation":[{"name":"Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. C.","family":"Welch","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Vonnahme","sequence":"additional","affiliation":[{"name":"Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Talwar","sequence":"additional","affiliation":[{"name":"Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Stojanovic","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Langer","sequence":"additional","affiliation":[{"name":"Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. M.","family":"Cocoros","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2022\/00000026\/00000012\/art00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T04:42:19Z","timestamp":1670388139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.22.0259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"alternative-id":["1027-3719(20221201)26:12L.1170;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.22.0259","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}